Clinical Trials · NCT06753864

A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

Name: A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 1Abaloparatide

Phase: Phase 1
Recruitment status: Not Yet Recruiting
Sponsor: The Affiliated Hospital of Qingdao University
Enrollment: 32
Start date: Jan 2025
Locations: 1 site, China
Primary endpoint: Peak Plasma Concentration (Cmax)

View Abaloparatide compound reference